

Gilead Sciences - 2020 Report

Date of publication: 30/06/2021

| Full Name (Art 1.01) | HCPS: City of Principal Practice HCOs: city where registered (Art 3) | Country of Principal Practice (Schedule 1) | Principal Practice Address (Art 3) | Unique country identifier OPTIONAL (Art 3) | Donations and Grants to HCOs (Art 3.01.1.a) | Contribution to costs of Events (Art 3.01.1.b & 3.01.2.a) | | | Fee for service and consultancy (Art 3.01.1 c & 3.01.2.c) | | TOTAL OPTIONAL |
|--|---|---|---|--|--|---|-------------------|------------------------|--|---|-------------------|
| | | | | | | Sponsorship agreements with HCOs/third parties appointed by HCOs to manage an Event | Registration Fees | Travel & Accommodation | Fees | Related expenses agreed in the fee for service or consultancy contract, including travel & accommodation relevant to the contract | |
| <i>INDIVIDUAL NAMED DISCLOSURE-one line per HCP(i.e. all transfers of value during a year for an individual HCP will be summed up:itemization should be available for the Individual Recipient or public authorities' consultation only, as appropriate)</i> | | | | | | | | | | | |
| FRIDRIKSDÓTTIR, RAGNHEIÐUR HULDA | Reykjavik | Iceland | Reykjafold 4 | | | | | | 170.771,59 ISK | 70.356,91 ISK | 241.128,50 ISK |
| <i>OTHER, NOT INCLUDED ABOVE-where information cannot be disclosed on an individual basis for legal reasons</i> | | | | | | | | | | | |
| H C P S | Aggregate amount attributable to transfers of value to such Recipients - Art 3.02 | | | | | | | | | | |
| | Number of Recipients in aggregate disclosure - Art 3.02 | | | | | | | | | | |
| | % of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - Art 3.02 | | | | | | | | | | |

| Full Name (Art 1.01) | HCPS: City of Principal Practice HCOs: city where registered (Art 3) | Country of Principal Practice (Schedule 1) | Principal Practice Address (Art 3) | Unique country identifier OPTIONAL (Art 3) | Donations and Grants to HCOs (Art 3.01.1.a) | Contribution to costs of Events (Art 3.01.1.b & 3.01.2.a) | | | Fee for service and consultancy (Art 3.01.1 c & 3.01.2.c) | | TOTAL OPTIONAL |
|--|---|---|---|--|--|---|-------------------|------------------------|--|---|-------------------|
| | | | | | | Sponsorship agreements with HCOs/third parties appointed by HCOs to manage an Event | Registration Fees | Travel & Accommodation | Fees | Related expenses agreed in the fee for service or consultancy contract, including travel & accommodation relevant to the contract | |
| <i>INDIVIDUAL NAMED DISCLOSURE-one Line per HCO(i.e. all transfers of value during a year for an individual HCO will be summed up:itemization should be available for the Individual Recipient or public authorities' consultation only, as appropriate)</i> | | | | | | | | | | | |
| LANDSPITALI UNIVERSITY HOSPITAL | Reykjavik | Iceland | Reykjafold 4 | | | | | | 332.260,25 ISK | | 332.260,25 ISK |
| <i>OTHER, NOT INCLUDED ABOVE-where information cannot be disclosed on an individual basis for legal reasons</i> | | | | | | | | | | | |
| H C O S | Aggregate amount attributable to transfers of value to such Recipients - Art 3.02 | | | | | | | | | | |
| | Number of Recipients in aggregate disclosure - Art 3.02 | | | | | | | | | | |
| | % of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - Art 3.02 | | | | | | | | | | |

AGGREGATE DISCLOSURE

R & D

Transfers of Value re Research & Development as defined - Article 3.04 and schedule 1

573.388,75 ISK